

Q3 2026 Earnings Presentation

October 29, 2026



Cautionary Notes

This release contains forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) uncertainty regarding the impact of our inclusion on the “unreliable entities list” by regulatory authorities in China; (v) uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, related court proceedings or administrative actions (including potential additional refund or relief programs), and other possible tariffs or trade protection measures and our efforts to mitigate the impact of such tariffs; (vi) our ability to manufacture robust instrumentation and consumables; (vii) the success of products and services competitive with our own; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) the impact of recently launched or pre-announced products and services on existing products and services; (x) our ability to modify our business strategies to accomplish our desired operational goals; (xi) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xii) our ability to further develop and commercialize our instruments, consumables, and products; (xiii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xiv) the risk of additional litigation or other liabilities arising against us in connection with previous acquisitions, including the GRAIL acquisition; (xv) our ability to obtain approval by third-party payors to reimburse patients for our products; (xvi) changes in the regulatory landscape and our ability to obtain regulatory clearance for our products from government agencies; (xvii) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xviii) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xix) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; and (xx) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Disclaimers

All financial metrics are non-GAAP excluding tariff refunds.

All reported revenue and revenue growth rates are presented on a year-over-year basis, excluding the impact of tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.

Reconciliation to non-GAAP and GAAP can be found in the Appendix, our earnings release and in the supplementary data on our website.

Year-over-year denotes a comparison against the same quarter of the prior fiscal year, while quarter-over-quarter, or sequential, denotes a comparison to the prior fiscal quarter.

All references to China refer to our Greater China Region, which includes Taiwan and Hong Kong.



Jacob Thaysen
Chief Executive Officer

Illumina Q3'26 Results Summary

Revenue

\$1.17B

+4.8% Organic | +7.6% Reported

ROW Organic Growth

+4.7%

Operating Margin

25.0%

Diluted EPS

\$1.44

Q3'26 NovaSeq™ X Placements


>80

Instruments

Regional Revenue

USCAN
\$665M
+9% Organic | +12% Reported

Greater China
\$59M
+7% Organic | +13% Reported



EMEALA
\$356M
(2%) Organic | ~Flat Reported

APAC
\$86M
+5% Organic | +5% Reported

USCAN = U.S. and Canada. EMEALA = Europe, Middle East, Africa, Latin America. APAC = Asia Pacific. ROW = rest-of-world.

All financial metrics are non-GAAP excluding tariff refunds. See Appendix for reconciliations to non-GAAP and GAAP financial measures.

Revenue and revenue growth exclude tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.


All values and growth rates are approximate. Growth rates are YoY. FX impacts as of 09/27/2026.



Ankur Dhingra
Chief Financial Officer

Illumina Q3'26 Revenue

(\$ in millions)



ROW = rest-of-world.
All financial metrics are non-GAAP excluding tariff refunds. See Appendix for reconciliations to non-GAAP and GAAP financial measures.
Revenue and revenue growth exclude tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.
Growth rates are YoY. FX impacts as of 09/27/2026.

Illumina Sequencing Revenue Detail


Sequencing Revenue ROW (\$ in millions)	Q1'25	Q2'25	Q3'25	Q4'25	2025	Q1'26	Q2'26	Q3'26
Product Revenue								
Consumables	\$640	\$690	\$707	\$713	\$2,750	\$687	\$734	\$748
Instruments	\$103	\$92	\$104	\$150	\$449	\$114	\$122	\$103
Sequencing Consumables Revenue Growth Rates								
<i>Total – ROW reported</i>	(0%)	2%	3%	11%	4%	7%	6%	6%
<i>Clinical – ROW reported</i>	8%	10%	12%	20%	12%	20%	15%	14%
<i>Research & Applied – ROW reported</i>	(11%)	(9%)	(8%)	(0%)	(7%)	(12%)	(7%)	(6%)

ROW = rest-of-world, excluding China.
Revenue and revenue growth exclude tariff refunds.
Growth rates shown are YoY.


Q3'26 High-Throughput Transition Updates

NovaSeq™ X Transition

NovaSeq X % of
HT Gb Shipped



NovaSeq X % of
HT Consumables Revenue



— Total

— Research & Applied

— Clinical

Gb = gigabases. HT = high-throughput.

All financial metrics are non-GAAP excluding tariff refunds. See Appendix for reconciliations to non-GAAP and GAAP financial measures.


Revenue and revenue growth exclude tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.

Illumina Q3'26 Revenue (Cont'd)

(\$ in millions)


Sequencing Instruments Revenue

*(1%) Organic | ~Flat Reported
(2%) ROW Organic*



Sequencing Service & Other Revenue

*+8% Organic | +7% Reported
+8% ROW Organic*



ROW = rest-of-world.

All financial metrics are non-GAAP excluding tariff refunds. See Appendix for reconciliations to non-GAAP and GAAP financial measures.


Revenue and revenue growth exclude tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.

Growth rates are YoY. FX impacts as of 09/27/2026.

Illumina Q3'26 Non-GAAP Financials


Gross Margin

+20 bps




Operating Margin

+50 bps



Diluted EPS

+7%



See Appendix for reconciliations of GAAP and non-GAAP financial measures.

All financial metrics are non-GAAP excluding tariff refunds. See Appendix for reconciliations to non-GAAP and GAAP financial measures.

Revenue and revenue growth exclude tariff refunds. Organic revenue growth also adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.

Illumina Q3'26 Cash Flow & Balance Sheet Items

Cash Flow Updates

\$419M

Cash Flow from Operations

\$41M

Capital Expenditures

\$378M

Free Cash Flow

Share Repurchase Program

~0.05M

Illumina Shares

\$191.11

Avg. Price per Share

~\$9M

Total Cost

Balance Sheet Updates

~\$1.34B

Cash, Cash Equivalents
& Short-Term Investments

~\$1.79B

Total Debt

~1.4x

Gross Leverage¹

See Appendix for reconciliations of GAAP and non-GAAP financial measures.

1. Gross debt to LTM EBITDA as of 09/27/2026; excludes tariff refunds.

Illumina Guidance for FY26

As of 10/29/2026. All growth rates reflect YoY trends.

	FY26 Guidance	Q4'26 Guidance
Non-GAAP Guidance		
Total Revenue, ex Tariff Refunds	\$4.64B - \$4.66B	\$1.22B - \$1.24B
<u>YoY Revenue Growth</u>		
Organic Growth, ROW¹	>5.0%	~4.5%
Organic Growth ¹	>4.0%	~4.5%
Organic Sequencing Growth ROW¹		
Consumables Revenue	+Mid-Single Digit	
Instruments Revenue	+Low-Single Digit	
Operating Margin, ex Tariff Refunds	~23.6%	~25%
EPS, ex Tariff Refunds	\$5.40 - \$5.45	\$1.51 - \$1.56
Tariff Refund Impact (Excl. from Guidance)		
Revenue	(\$37M)	
Operating Margin	+90 bps	
EPS	+\$0.18	

See statement regarding use of non-GAAP financial measures.

FX impacts as of 09/27/2026.

1. Organic revenue growth adjusts for the impact of currency and acquisitions. Rest-of-world organic growth further excludes our Greater China region.

Q&A



Jacob Thaysen
Chief Executive Officer



Ankur Dhingra
Chief Financial Officer

Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted earnings per share, gross margin, operating margin, and free cash flow, among others, in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial charges such as amortization of acquired intangible assets, among others, that are listed in the reconciliations of GAAP and non-GAAP financial measures included in this press release. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Non-GAAP operating margin and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in this release.

The company provides forward-looking guidance on a non-GAAP basis. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related costs, fair value adjustments to contingent consideration, gains and losses from strategic investments, asset impairments, restructuring activities, and the ultimate outcome of pending litigation, among others, without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) uncertainty regarding the impact of our inclusion on the "unreliable entities list" by regulatory authorities in China; (v) uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, related court proceedings or administrative actions (including potential additional refund or relief programs), and other possible tariffs or trade protection measures and our efforts to mitigate the impact of such tariffs; (vi) our ability to manufacture robust instrumentation and consumables; (vii) the success of products and services competitive with our own; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) the impact of recently launched or pre-announced products and services on existing products and services; (x) our ability to modify our business strategies to accomplish our desired operational goals; (xi) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xii) our ability to further develop and commercialize our instruments, consumables, and products; (xiii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xiv) the risk of additional litigation or other liabilities arising against us in connection with previous acquisitions, including the GRAIL acquisition; (xv) our ability to obtain approval by third-party payors to reimburse patients for our products; (xvi) changes in the regulatory landscape and our ability to obtain regulatory clearance for our products from government agencies; (xvii) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xviii) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xix) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; and (xx) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

###

Illumina, Inc.
Condensed Statements of Cash Flows
(In millions)
(unaudited)

	Three Months Ended		Nine Months Ended	
	September 27, 2026	September 28, 2025	September 27, 2026	September 28, 2025
Net cash provided by operating activities	\$ 419	\$ 284	\$ 909	\$ 758
Net cash provided by (used in) investing activities	50	(51)	(438)	(163)
Net cash used in financing activities	(223)	(115)	(602)	(681)
Effect of exchange rate changes on cash and cash equivalents	3	(2)	2	9
Net increase (decrease) in cash and cash equivalents	249	116	(129)	(77)
Cash and cash equivalents, beginning of period	1,040	934	1,418	1,127
Cash and cash equivalents, end of period	<u>\$ 1,289</u>	<u>\$ 1,050</u>	<u>\$ 1,289</u>	<u>\$ 1,050</u>
Calculation of free cash flow:				
Net cash provided by operating activities	\$ 419	\$ 284	\$ 909	\$ 758
Purchases of property and equipment	(41)	(31)	(118)	(93)
Free cash flow (a)	<u>\$ 378</u>	<u>\$ 253</u>	<u>\$ 791</u>	<u>\$ 665</u>

- (a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.

Illumina, Inc.
Results of Operations - Non-GAAP
(unaudited)

TABLE 1: RECONCILIATION OF REVENUE GROWTH:

	Three Months Ended September 27, 2026	Nine Months Ended September 27, 2026
Revenue growth	4.2 %	6.2 %
Impact of tariff refunds	3.4 %	1.1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	7.6 %	7.3 %
Impact of acquisitions	(2.4)%	(2.1)%
Impact of currency exchange rates	(0.4)%	(1.0)%
Organic revenue growth (non-GAAP) (a)	4.8 %	4.2 %
Impact of China	(0.1)%	1.2 %
ROW organic revenue growth (non-GAAP) (a)	4.7 %	5.4 %

TABLE 2: RECONCILIATION OF GAAP AND NON-GAAP DILUTED EARNINGS PER SHARE:

	Three Months Ended		Nine Months Ended	
	September 27, 2026	September 28, 2025	September 27, 2026	September 28, 2025
GAAP diluted earnings per share	\$ 1.43	\$ 0.98	\$ 3.65	\$ 3.29
Acquisition-related costs (d)	0.10	0.17	0.33	0.28
Transformational initiatives (e)	0.03	0.08	0.10	0.33
Strategic investment loss (gain), net (f)	0.19	(0.04)	0.27	(0.90)
Intangible impairment	—	—	—	0.15
Other (g)	—	—	—	0.03
Provision for income taxes (h)	(0.13)	0.15	(0.27)	0.31
Non-GAAP diluted earnings per share (b)	1.62	1.34	4.08	3.49
Tariff refunds (i)	(0.18)	—	(0.18)	—
Non-GAAP diluted earnings per share, excluding tariff refunds (b)	<u>\$ 1.44</u>	<u>\$ 1.34</u>	<u>\$ 3.90</u>	<u>\$ 3.49</u>

Illumina, Inc.
Results of Operations - Non-GAAP (continued)
(unaudited)

TABLE 3: RECONCILIATION OF GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:

	Three Months Ended				Nine Months Ended			
	September 27, 2026		September 28, 2025		September 27, 2026		September 28, 2025	
<i>(Dollars in millions)</i>								
GAAP gross profit (c)	\$ 830	73.5 %	\$ 733	67.6 %	\$ 2,321	68.7 %	\$ 2,111	66.3 %
Acquisition-related costs (d)	20	1.8 %	16	1.5 %	64	1.9 %	50	1.6 %
Transformational initiatives (e)	—	— %	1	0.1 %	—	— %	3	0.1 %
Intangible impairment	—	— %	—	— %	—	— %	23	0.7 %
Non-GAAP gross profit (b)	850	75.3 %	750	69.2 %	2,385	70.6 %	2,187	68.7 %
Tariff refunds (i)	(41)	(5.9)%	—	— %	(41)	(2.0)%	—	— %
Non-GAAP gross profit, excluding tariff refunds (b)	\$ 809	69.4 %	\$ 750	69.2 %	\$ 2,344	68.6 %	\$ 2,187	68.7 %
GAAP operating profit	\$ 305	27.0 %	\$ 227	21.0 %	\$ 759	22.5 %	\$ 606	19.0 %
Acquisition-related costs (d)	15	1.4 %	26	2.5 %	50	1.5 %	44	1.4 %
Transformational initiatives (e)	5	0.4 %	12	1.0 %	15	0.4 %	51	1.6 %
Intangible impairment	—	— %	—	— %	—	— %	23	0.7 %
Other (g)	—	— %	—	— %	—	— %	5	0.2 %
Non-GAAP operating profit (b)	325	28.8 %	265	24.5 %	824	24.4 %	729	22.9 %
Tariff refunds (i)	(33)	(3.8)%	—	— %	(33)	(1.3)%	—	— %
Non-GAAP operating profit, excluding tariff refunds (b)	\$ 292	25.0 %	\$ 265	24.5 %	\$ 791	23.1 %	\$ 729	22.9 %

Illumina, Inc.
Results of Operations - Non-GAAP (continued)
(unaudited)

TABLE 4: RECONCILIATION OF GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:

	Three Months Ended				Nine Months Ended			
	September 27, 2026		September 28, 2025		September 27, 2026		September 28, 2025	
<i>(Dollars in millions)</i>								
GAAP R&D expense	\$ 244	21.6 %	\$ 229	21.1 %	\$ 736	21.8 %	\$ 728	22.9 %
Acquisition-related costs (d)	(1)	(0.1)%	—	— %	(3)	(0.1)%	(1)	— %
Transformational initiatives (e)	—	— %	(1)	— %	—	— %	(15)	(0.5)%
Non-GAAP R&D expense	<u><u>\$ 243</u></u>	<u><u>21.5 %</u></u>	<u><u>\$ 228</u></u>	<u><u>21.1 %</u></u>	<u><u>\$ 733</u></u>	<u><u>21.7 %</u></u>	<u><u>\$ 712</u></u>	<u><u>22.4 %</u></u>
GAAP SG&A expense	\$ 281	24.9 %	\$ 277	25.5 %	\$ 826	24.4 %	\$ 777	24.4 %
Acquisition-related costs (d)	6	0.4 %	(11)	(1.0)%	16	0.5 %	6	0.2 %
Transformational initiatives (e)	(5)	(0.4)%	(10)	(0.9)%	(15)	(0.4)%	(33)	(1.0)%
Other (g)	—	— %	—	— %	—	— %	(5)	(0.2)%
Non-GAAP SG&A expense	<u><u>\$ 282</u></u>	<u><u>24.9 %</u></u>	<u><u>\$ 256</u></u>	<u><u>23.6 %</u></u>	<u><u>\$ 827</u></u>	<u><u>24.5 %</u></u>	<u><u>\$ 745</u></u>	<u><u>23.4 %</u></u>
GAAP other (expense) income, net	\$ (41)	(3.6)%	\$ (7)	(0.6)%	\$ (78)	(2.3)%	\$ 103	3.2 %
Strategic investment loss (gain), net (f)	29	2.5 %	(6)	(0.6)%	42	1.2 %	(141)	(4.4)%
Non-GAAP other expense, net	<u><u>\$ (12)</u></u>	<u><u>(1.1)%</u></u>	<u><u>\$ (13)</u></u>	<u><u>(1.2)%</u></u>	<u><u>\$ (36)</u></u>	<u><u>(1.1)%</u></u>	<u><u>\$ (38)</u></u>	<u><u>(1.2)%</u></u>

- (a) Revenue growth, excluding tariff refunds adjusts for the tariff refund to customers. Organic revenue growth adjusts for the impact from the tariff refund to customers, acquisitions and currency movements, which is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges. Rest of World (ROW) organic revenue growth also adjusts for the impact from our China region.
- (b) Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP diluted earnings per share and non-GAAP operating profit exclude the effects of the pro forma adjustments as detailed above. Non-GAAP operating margin and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.
- (c) Reconciling amounts are recorded in cost of revenue.
- (d) Amounts for Q3 2026 and YTD 2026 consist primarily of:
 - Amortization of intangible assets of \$18 million and \$53 million (cost of revenue)
 - Amortization of inventory fair value step-up for SomaLogic of \$2 million and \$10 million (cost of revenue)
 - Expenses for the SomaLogic and GRAIL acquisitions of \$5 million and \$26 million (operating expense)
 - Net gains on contingent consideration liabilities of (\$11) million and (\$43) million (operating expense)
 Amounts for Q3 2025 and YTD 2025 consist primarily of:
 - Amortization of intangible assets of \$16 million and \$50 million (cost of revenue)
 - Expenses for the SomaLogic and GRAIL acquisitions of \$4 million and \$19 million (operating expense)
 - Net losses (gains) on contingent consideration liabilities of \$3 million and (\$29) million (operating expense)
 - Lease impairment of \$4 million (operating expense)
- (e) Amounts for Q3 2026 and YTD 2026 consist primarily of implementation costs to upgrade our ERP system. Amounts for Q3 2025 consist primarily of implementation costs to upgrade our ERP system. Amounts for YTD 2025 consist primarily of employee severance costs from restructuring activities and costs related to the ERP upgrade.
- (f) Amounts consist of realized and unrealized gains and losses and impairments on our investments.
- (g) Amount consists of \$3 million for costs related to board membership changes and \$2 million for a legal accrual.
- (h) Amounts represent the aggregate of the difference between book and tax accounting related to stock-based compensation cost and the tax impact related to non-GAAP adjustments. Amounts for Q3 2025 and YTD 2025 also include a one-time \$42 million valuation allowance adjustment recorded in Q3 2025 against deferred tax assets associated with certain U.S. foreign tax credits as a result of the U.S. tax legislation that was signed on July 4, 2025.
- (i) Amounts represent the impacts of IEEPA tariff refunds, consisting primarily of the \$79 million benefit recognized as a reduction to cost of revenue in Q3 2026 and the related reduction to revenue of \$37 million for the portion of tariff refunds that we expect to credit to customers.

Illumina, Inc.
Results of Operations - Non-GAAP (continued)
(unaudited)

TABLE 5: RECONCILIATION OF GAAP AND NON-GAAP TAX PROVISION:

<i>(Dollars in millions)</i>	Three Months Ended				Nine Months Ended			
	September 27, 2026		September 28, 2025		September 27, 2026		September 28, 2025	
GAAP tax provision	\$ 44	16.4 %	\$ 70	31.8 %	\$ 120	17.6 %	\$ 193	27.2 %
Income tax provision (b)	1		(1)		1		(8)	
Non-GAAP tax expense (c)	19		(22)		40		(41)	
Non-GAAP tax provision (a)	<u><u>\$ 64</u></u>	<u><u>20.5 %</u></u>	<u><u>\$ 47</u></u>	<u><u>18.6 %</u></u>	<u><u>\$ 161</u></u>	<u><u>20.5 %</u></u>	<u><u>\$ 144</u></u>	<u><u>20.8 %</u></u>

- (a) Non-GAAP tax provision excludes the effects of the pro forma adjustments detailed above, which have been excluded to assist investors in analyzing and assessing past and future operating performance.
- (b) Amounts represent the difference between book and tax accounting related to stock-based compensation cost.
- (c) Non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed in Table 2. Amounts for Q3 2025 and YTD 2025 also include a one-time \$42 million valuation allowance adjustment recorded in Q3 2025 against deferred tax assets associated with certain U.S. foreign tax credits as a result of the U.S. tax legislation that was signed on July 4, 2025.

Illumina, Inc.
Results of Operations - Tariff Refund Revenue Impact
(In millions)
(unaudited)

TABLE 1: TARIFF REFUND REVENUE IMPACT BY SOURCE:

Revenue was negatively impacted in the quarter due to customer refunds accrued as a result of the benefit from IEEPA tariff refunds we recognized in the quarter. The table below shows revenue impact by product category.

	Three Months and Nine Months Ended	
	September 27, 2026	
Sequencing consumables revenue	\$	28
Sequencing instruments revenue		4
Sequencing service and other revenue		3
Total sequencing revenue		35
Total microarray revenue		2
Total revenue	\$	37

TABLE 2: TARIFF REFUND REVENUE IMPACT BY REGION:

Revenue was negatively impacted in the quarter due to customer refunds accrued as a result of the benefit from IEEPA tariff refunds we recognized in the quarter. The table below shows revenue impact by region.

	Three Months and Nine Months Ended	
	September 27, 2026	
United States and Canada	\$	28
Europe, Middle East, Africa and Latin America		9
Total revenue	\$	37

Illumina, Inc.
Results of Operations - Revenue by Source
(unaudited)

TABLE 1: RECONCILIATION OF REVENUE GROWTH - REVENUE BY SOURCE:

	Three Months Ended September 27, 2026	Nine Months Ended September 27, 2026
Sequencing consumables revenue growth	2 %	4 %
Impact of tariff refunds	4 %	1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	6 %	5 %
Impact of currency exchange rates	— %	(1)%
Organic revenue growth (non-GAAP) (a)	6 %	4 %
ROW sequencing consumables revenue growth	2 %	5 %
Impact of tariff refunds	4 %	1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	6 %	6 %
Impact of currency exchange rates	(1)%	(1)%
ROW organic revenue growth (non-GAAP) (a)	5 %	5 %
Sequencing instruments revenue growth	(5)%	11 %
Impact of tariff refunds	5 %	1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	— %	12 %
Impact of currency exchange rates	(1)%	(1)%
Organic revenue growth (non-GAAP) (a)	(1)%	11 %
Impact of China	(1)%	1 %
ROW organic revenue growth (non-GAAP) (a)	(2)%	12 %
Sequencing service and other revenue growth	5 %	8 %
Impact of tariff refunds	2 %	1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	7 %	9 %
Impact of currency exchange rates	1 %	(1)%
Organic revenue growth (non-GAAP) (a)	8 %	8 %
Impact of China	— %	1 %
ROW organic revenue growth (non-GAAP) (a)	8 %	9 %
Microarray revenue growth	30 %	17 %
Impact of tariff refunds	2 %	— %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	32 %	17 %
Impact of acquisitions	(31)%	(25)%
Impact of currency exchange rates	— %	(1)%
Organic revenue growth (non-GAAP) (a)	1 %	(9)%
Impact of China	1 %	1 %
ROW organic revenue growth (non-GAAP) (a)	2 %	(8)%

(a) Revenue growth, excluding tariff refunds adjusts for the tariff refund to customers. Organic revenue growth adjusts for the impact from the tariff refund to customers, acquisitions and currency movements, which is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges. Rest of World (ROW) organic revenue growth also adjusts for the impact from our China region.

Illumina, Inc.
Results of Operations - Revenue by Region
(unaudited)

TABLE 1: RECONCILIATION OF REVENUE GROWTH - REVENUE BY REGION:

	Three Months Ended September 27, 2026	Nine Months Ended September 27, 2026
USCAN revenue growth	7 %	9 %
Impact of tariff refunds	5 %	2 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	12 %	11 %
Impact of acquisitions	(3)%	(2)%
Impact of currency exchange rates	— %	— %
Organic revenue growth (non-GAAP) (a)	9 %	9 %
EMEALA revenue growth	(2)%	3 %
Impact of tariff refunds	2 %	1 %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	— %	4 %
Impact of acquisitions	(1)%	(1)%
Impact of currency exchange rates	(1)%	(3)%
Organic revenue growth (non-GAAP) (a)	(2)%	— %
APAC revenue growth	5 %	11 %
Impact of tariff refunds	— %	— %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	5 %	11 %
Impact of acquisitions	(2)%	(6)%
Impact of currency exchange rates	2 %	1 %
Organic revenue growth (non-GAAP) (a)	5 %	6 %
Greater China revenue growth (b)	13 %	(11)%
Impact of tariff refunds	— %	— %
Revenue growth, excluding tariff refunds (non-GAAP) (a)	13 %	(11)%
Impact of acquisitions	(5)%	(4)%
Impact of currency exchange rates	(1)%	(1)%
Organic revenue growth (non-GAAP) (a)(b)	7 %	(16)%

United States and Canada (USCAN), Europe, Middle East, Africa and Latin America (EMEALA), Asia-Pacific (APAC)

- (a) Revenue growth, excluding tariff refunds adjusts for the tariff refund to customers. Organic revenue growth adjusts for the impact from the tariff refund to customers, acquisitions and currency movements, which is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges.
- (b) Region includes revenue from China, Taiwan, and Hong Kong.